Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

drug-resistant tuberculosis - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

drug-resistant tuberculosis

MONDO:0041806

Find Clinical TrialsTrials

Overview

Tuberculosis disease caused by Mycobacterium tuberculosis isolate that is resistant to one or more of the antitubercular medications.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials8 registered · 5 recruiting

Diagnosis

Biomarker and diagnostic research for drug-resistant tuberculosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for drug-resistant tuberculosis. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for drug-resistant tuberculosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for drug-resistant tuberculosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

8 clinical trials registered, 5 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 2 PHASE3, 4 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05553236](https://clinicaltrials.gov/study/NCT05553236)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:59 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 8 active clinical trials a good fit for my situation?
→What is the current development status of dimethyl sulfoxide, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Disease patterns and progression	88	35%
Research summaries	77	30%
Laboratory research	23	9%
Clinical study results	21	8%
Other research	17	7%
Testing and diagnosis research	12	5%
Patient case studies	10	4%
New treatment approaches	5	2%

Kisho

drug-resistant tuberculosis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Diagnosis and Therapeutic Challenges of Drug-Resistant Tuberculosis Infection After Kidney Transplantation: A Rare Case Report.

drug-resistant tuberculosis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Diagnosis and Therapeutic Challenges of Drug-Resistant Tuberculosis Infection After Kidney Transplantation: A Rare Case Report.